Urologix logo

Urologix(OTC) ULGX

Market Cap$2.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)-100%
5 Year-97%
1 Year+9,900%
1 Month+0%
$0.00
+0.00%
+0.00Today
Urologix last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-08
Urologix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-10
1 month+0%USD 0.002026-07-27
3 month+0%USD 0.002026-05-29
Year to date+0%USD 0.002025-12-29
1 year+9,900%USD 0.002025-09-04
3 year+0%USD 0.002023-09-01
5 year-96.67%USD 0.002021-09-08
Since inception-100%USD 15.251996-05-30

Urologix Financials at a Glance

Market Cap

$2.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$12.19M

Net Income (TTM)

-$4.67M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-730.26 (Low)

Price

$0.00

Volume

83,334

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.02

Estimated Earnings Date

Feb 7, 2025

ULGX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Urologix

Urologix, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in minimally invasive treatments for benign prostatic hyperplasia (BPH). Established in 1991, the company focuses on innovative solutions that enhance patient comfort and improve treatment outcomes.

Products and Services
  • Cooled ThermoTherapy system for targeted microwave energy application
  • Prostiva RF Therapy System for radio frequency energy delivery
  • Comprehensive support for healthcare professionals and patients
Growth Outlook
  • Increasing demand for minimally invasive BPH treatments drives market potential
  • Expansion of product offerings enhances competitive positioning
  • Strategic partnerships may lead to broader market access
Financial Highlights
  • Recent quarterly revenue of $2.8 million reflects stable demand
  • Gross profit margin of 46.9% indicates effective cost management
  • Operating expenses decreased, improving operational efficiency
Urologix, Inc. operates in the healthcare sector, specifically within the medical devices industry. The company has developed a reputation for its innovative approaches to treating BPH, a condition affecting millions of men. The Cooled ThermoTherapy and Prostiva RF Therapy systems are at the forefront of its product line, designed to provide effective relief while minimizing discomfort. The growth outlook for Urologix is promising, driven by an increasing awareness of minimally invasive treatment options among patients and healthcare providers. The company is well-positioned to capitalize on this trend, with plans to expand its product offerings and explore strategic partnerships that could enhance its market presence. Financially, Urologix has shown resilience, with a recent quarterly revenue of $2.8 million, reflecting consistent demand for its products. The gross profit margin of 46.9% demonstrates effective cost management strategies, while a decrease in operating expenses suggests improved operational efficiency. These financial metrics indicate a solid foundation for potential growth and profitability in the future.
AI Generated • Sep 22, 2026

Industry

Healthcare Equipment and Supplies

Headquarters

Minneapolis, MN 55447, US

ULGX Financials

Key Financial Metrics (TTM)

Gross Margin

42.80%

Operating Margin

-48.68%

Net Income Margin

-53.45%

Return on Equity

232.06%

Return on Capital

N/A

Return on Assets

-134.25%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

21.82M

Volume

83.33K

Avg. Volume

1.30K

Financials (TTM)

Gross Profit

$5.82M

Operating Income

-$3.94M

EBITDA

-$414.00K

Operating Cash Flow

-$263.00K

Capital Expenditure

-$30.00K

Free Cash Flow

-$293.00K

Cash & ST Invst.

$492.00K

Total Debt

$5.33M

Urologix Performance Analysis

Urologix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42014-06-30-1.8%
Q12014-09-30-8.3%
Q22014-12-311.9%
Q32015-03-31-9.2%
Urologix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42014-06-30-117.9%
Q12014-09-3088.1%
Q22014-12-3119.2%
Q32015-03-312.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2015YOY CHG

Revenue

$2.80M

-16.7%

Gross Profit

$1.31M

+54.4%

Gross Margin

46.89%

N/A

Market Cap

$2.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$36.07

N/A

Employees

61

N/A

Net Income

-$349.00K

+79.0%

EBITDA

-$42.00K

+96.9%

Quarterly Fundamentals

Name
Q3 2015YOY CHG

Total Cash

$492.00K

-39.7%

Total Debt

$5.33M

-0.0%

Accounts Receivable

$1.39M

-22.5%

Inventory

$1.32M

-0.2%

Long Term Debt

$3.54M

-19.9%

Short Term Debt

$1.80M

+95.1%

Return on Assets

-1.34%

N/A

Return on Invested Capital

-5.04%

N/A

Free Cash Flow

-$42.00K

+90.7%

Operating Cash Flow

-$34.00K

+92.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COTQFCotinga Pharmaceuticals Inc.
$0.00+0.00%
LPTILongport, Inc.
$0.00+0.00%
SVSOSheerVision, Inc.
$0.00+0.00%
THMOThermoGenesis Holdings, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
VEEAVeea
$5.99+54.79%
TAT&T
$22.72-7.63%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.12-1.98%
SPCXSpace Exploration Technologies
$164.43+2.40%

Questions About ULGX

What is the current price of Urologix?

Urologix is trading at $0.00 per share.

What is the 52-week range for Urologix?

Over the past 52 weeks, Urologix has traded between $0.00 and $0.02.

How much debt does Urologix have?

Urologix total debt is unavailable.

How much cash does Urologix have on hand?

Urologix does not have cash on hand data available.

What is Urologix’s dividend yield?

Urologix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.